An Open-Label Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 as Monotherapy in Patients With Advanced Solid Tumors
Latest Information Update: 05 May 2026
At a glance
- Drugs HH 101 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Huahui Health
Most Recent Events
- 05 May 2026 New trial record